Processa Pharmaceuticals Inc (PCSA) 13F Holdings Overview (Q2 2026)

PCSA ranks #9646 out of 37696 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

PCSA is a disclosed holding of Ken Griffin (Citadel Advisors LLC), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

12 institutions disclose a position in PCSA, but none treat it as a major bet — even Connective Capital Management, LLC, its most concentrated holder, allocates just 0.1% of its own portfolio to it.

Jones Financial Companies Lllp has trimmed its PCSA position for two straight quarters, cutting it by $7.0 while still holding $13.0.

PCSA reported a net loss of $13.4M over the trailing twelve months.

• Not yet profitable — net loss of $13.4M over the trailing twelve months
• Net income declined year over year, from -$12.9M to -$13.4M
• Operating cash flow was negative, using $11.4M in cash
• Current ratio of 2.54x — enough short-term assets to cover short-term liabilities
• Liabilities run 8701.37x equity — a highly leveraged balance sheet worth noting